8-K filed Jun 9, 2026 at 17:04 ET
Vistagen announced that its fasedienol clinical program has exceeded ICH E1 minimum safety exposure recommendations, with over 1,500 subjects receiving at least one dose, over 300 with at least 6 months of exposure, and over 100 with at least 12 months. This is a regulatory milestone for the NDA pathway, but the company has not yet aligned with the FDA on specific requirements. Topline results from the pivotal PALISADE-4 Phase 3 trial are expected in Q2 2026, and from the Phase 2 repeat dose study in Q3 2026.